目的:对益生菌增效治疗幽门螺杆菌(Helicobacter pylori,H.pylori)感染的系统评价/Meta分析进行再评价研究.方法:计算机检索CBM、CNKI、Wanfang Data、VIP Data、the Cochrane library、PubMed、Embase数据库,收集关于益生菌增效治疗H.p...目的:对益生菌增效治疗幽门螺杆菌(Helicobacter pylori,H.pylori)感染的系统评价/Meta分析进行再评价研究.方法:计算机检索CBM、CNKI、Wanfang Data、VIP Data、the Cochrane library、PubMed、Embase数据库,收集关于益生菌增效治疗H.pylori感染的系统评价/Meta分析文章,检索时间均从建库至2014-10.由两位研究者按照纳入排除标准独立筛选文献、提取资料后,采用OQAQ(Overview Quality Assessment of Questionnaire)量表评价纳入研究质量,并采用GRADE(Grade o f R e c o m m e n d a t i o n,A s s e s s m e n t,Development,and Evaluation)系统进行证据质量分级.结果:共纳入11个相关Meta分析,11个研究均评价了益生菌增效治疗H.pylori的根除率及总不良反应发生率,其中3个研究详细评价了抗H.pylori具体不良反应发生率,OQAQ平均得分3.82分.GRADE系统的证据质量评价结果显示证据质量等级普遍较低.结论:当前益生菌增效治疗H.pylori感染具有一定的优势,但Meta分析的总体质量较差,证据水平较低,临床医生应根据实际情况进行循证决策.展开更多
A capsulated microdose 14C-urea breath test (14C-UBT) was developed to detect Helicobacter pylori (HP) infection in 137 patients (54 HP negative and 83 HP positive individuals)to whom a single dose of 3. 7ｘ 104 Bq of...A capsulated microdose 14C-urea breath test (14C-UBT) was developed to detect Helicobacter pylori (HP) infection in 137 patients (54 HP negative and 83 HP positive individuals)to whom a single dose of 3. 7ｘ 104 Bq of 14C-urea in a capsule was given. Samples of exhaled gas were collected at the sib, 10th, 15th. 20th, 25th, 30th, 45th and 60th minute after the administration and the peak value of exhaled 14CO2 was found in the samples collected at the 25th minute. This peak value was taken as the measuring point and directly expressed as Bq/mmol CO2 to develop a new detecting method. Then its results were compared with those of HP culture and histological examination. It was found that the samples collected on the 25th minute showed a sensitivity of 97. 06%, specificity of 95. 12%, positive predictive value of 97. 06% and negative predictive value of 95. 12% respectively when the mean value of 14CO2 in HP negative subjects ±3s on the 25th minute was taken as the critical value. This suggests that the capsule-based microdose 14C-UBT may replace conventional 14C-UBT using a larger dose of (1. 85-3. 7)ｘ 105 Bq for it is non-invasive, safe, rapid, accurate, simple and economic.展开更多
文摘目的:对益生菌增效治疗幽门螺杆菌(Helicobacter pylori,H.pylori)感染的系统评价/Meta分析进行再评价研究.方法:计算机检索CBM、CNKI、Wanfang Data、VIP Data、the Cochrane library、PubMed、Embase数据库,收集关于益生菌增效治疗H.pylori感染的系统评价/Meta分析文章,检索时间均从建库至2014-10.由两位研究者按照纳入排除标准独立筛选文献、提取资料后,采用OQAQ(Overview Quality Assessment of Questionnaire)量表评价纳入研究质量,并采用GRADE(Grade o f R e c o m m e n d a t i o n,A s s e s s m e n t,Development,and Evaluation)系统进行证据质量分级.结果:共纳入11个相关Meta分析,11个研究均评价了益生菌增效治疗H.pylori的根除率及总不良反应发生率,其中3个研究详细评价了抗H.pylori具体不良反应发生率,OQAQ平均得分3.82分.GRADE系统的证据质量评价结果显示证据质量等级普遍较低.结论:当前益生菌增效治疗H.pylori感染具有一定的优势,但Meta分析的总体质量较差,证据水平较低,临床医生应根据实际情况进行循证决策.
文摘A capsulated microdose 14C-urea breath test (14C-UBT) was developed to detect Helicobacter pylori (HP) infection in 137 patients (54 HP negative and 83 HP positive individuals)to whom a single dose of 3. 7ｘ 104 Bq of 14C-urea in a capsule was given. Samples of exhaled gas were collected at the sib, 10th, 15th. 20th, 25th, 30th, 45th and 60th minute after the administration and the peak value of exhaled 14CO2 was found in the samples collected at the 25th minute. This peak value was taken as the measuring point and directly expressed as Bq/mmol CO2 to develop a new detecting method. Then its results were compared with those of HP culture and histological examination. It was found that the samples collected on the 25th minute showed a sensitivity of 97. 06%, specificity of 95. 12%, positive predictive value of 97. 06% and negative predictive value of 95. 12% respectively when the mean value of 14CO2 in HP negative subjects ±3s on the 25th minute was taken as the critical value. This suggests that the capsule-based microdose 14C-UBT may replace conventional 14C-UBT using a larger dose of (1. 85-3. 7)ｘ 105 Bq for it is non-invasive, safe, rapid, accurate, simple and economic.
